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macoeconomic evidence of TNF inhibitors in AS and to provide
a critique of the methodology using Drummond’s 10-point
checklist. METHODS: A systematic literature search was con-
ducted by one researcher among publications in peer-reviewed
journals from January 2000 to April 2006 through electronic
databases (Medline, Embase, and Cochrane Database). Only
studies that provided economic evaluations of TNF inhibitors in
AS were included in the review. RESULTS: The search yielded a
total of eight cost studies. Only four met study inclusion crite-
ria. Three of the four studies were cost-effectiveness analysis and
two of the four compared etanercept and inﬂiximab in patients
with AS. The analytical time frame ranged from one year to 30
years. Costs and effects were appropriately discounted and 
sensitivity analysis was conducted to test the robustness of 
the model assumptions. Outcomes were presented as cost per
quality-adjusted life years (QALYs) or cost per Assessment in
Ankylosing Spondylitis Response Criteria. The incremental cost-
utility ratio of etanercept or inﬂiximab varied between US
$50,000–$250,000 per QALY when compared with usual care.
CONCLUSION: The costs per QALY ratios for the TNF
inhibitors seem to be a little higher than the normally accepted
societal thresholds ($50,000/QALY). The heterogeneity in the
cost-effectiveness results could be due to factors like patient
demographics, funding source and methodological variables.
Nonetheless, TNF inhibitors are a valuable treatment option and
further pharmacoeconomic analyses need be conducted to fully
evaluate their potential in patients with AS.
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OBJECTIVES: To assess the utilization patterns and costs for
health care services for chronic arthritis treatment among chil-
dren and adolescents enrolled in a state Medicaid program.
METHODS: A cross-sectional, descriptive analysis of a state
Medicaid administrative claims dataset was conducted. Medical
services claims with a primary diagnosis code for rheumatic dis-
eases (ICD-9-CM 696.0, 695.4, 710.X, 714.0, 714.2, 714.3X,
and 720.X) during calendar year 2003 for recipients under 21
years of age were extracted. Prescription medication claims were
extracted using de-identiﬁed unique recipient numbers obtained
from medical services claims. Prevalence and medical services use
rates were calculated by demographic categories. Costs were
reported from the perspective of Medicaid. RESULTS: There
were 171 children and adolescents who used medical services for
care of chronic arthritis, at an overall rate of 0.8/1000 recipi-
ents. The highest rates by demographic groups occurred among
females (1.0/1000), whites (0.9/1000), and recipients between
15–20 years of age (1.9/1000). Ofﬁce visits accounted for the
majority of medical services utilized (99%), at a rate of 3.4
visits/1000 recipients. Medicaid paid approximately $415/child
and adolescent recipient for chronic arthritis-related medical ser-
vices during the year. Dollars paid for ofﬁce visits accounted for
85% of the medical services costs at an average cost of $86 per
visit. A majority of the sample (63%) had a diagnosis for
rheumatoid arthritis (RA)/juvenile rheumatoid arthritis (JRA).
Among these children and adolescents, 62% had at least one pre-
scription claim for a narcotic analgesic, NSAID, oral steroid,
DMARD, or biologic agent at an average cost of $74/claim.
CONCLUSION: The prevalence and medical services utilization
patterns for chronic arthritis among children and adolescent
recipients in this State Medicaid population differed by demo-
graphic characteristics. Ofﬁce visits accounted for a majority of
medical services use and dollars. Most of the children and ado-
lescents with chronic arthritis had a diagnosis for RA/JRA.
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OBJECTIVES: Mixed treatment comparison is a generalisation
of meta-analysis. Instead of the same treatment for a disease
being tested in a number of studies, a number of different inter-
ventions are considered. Meta-regression is also a generalisation
of meta-analysis which explains the heterogeneity between the
treatment effects in the studies by regressing on study level
covariables. Our focus is where there are several different treat-
ments considered in a number of studies, and where differences
in efﬁcacy can be explained by differences in the study settings.
METHODS: We develop methods for simultaneously compar-
ing several treatments and adjusting for study level covariables
by combining ideas from mixed treatment comparisons and
meta-regression. We use a case study from rheumatoid arthritis.
We identiﬁed relevant trials of biologic verses standard therapy
or placebo and extracted the doses, comparators and patient
baseline characteristics. Efﬁcacy is measured using the log odds
ratio of achieving ACR50 responder status at 6 months. A
random-effects meta-regression model is ﬁtted which adjusts the
log odds ratio of an ACR50 response if treated with a biologic
therapy compared to placebo for study level prognostic factors.
The logit probability of a response is regressed onto a treatment
indicator and prognostic covariables. A different random effect
distribution on the log odds ratios is allowed for each different
treatment. This enables the odds ratio for each treatment to be
found as a function of the prognostic factors. RESULTS: The
apparent differences in the randomised trials between TNF
antagonists biologics are explained by differences in prognostic
factors and the analysis suggest that these drugs as a class are
not different from each other. CONCLUSION: We deﬁne a
methodology for combining meta-regression techniques with
ideas from mixed treatment comparisons. This allows different
treatments for the same condition to be compared whilst adjust-
ing for difference in the study populations.
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OBJECTIVES: To evaluate switching patterns among anti-TNFs
in rheumatoid arthritis (RA) patients. METHODS: A retrospec-
tive study utilizing the PharMetrics managed-care claims data-
base was conducted. The ﬁrst anti-TNF encounter among RA
patients between January 1, 2001 and January 1, 2004 was iden-
tiﬁed. Patients were required to have a minimum of 12-months
of continuous plan eligibility prior to and following their index
date. Three mutually exclusive cohorts were developed based on
their index biologic therapy (inﬂiximab, etanercept and adali-
mumab) plus methotrexate (MTX). The rates of switching and
